CytomX Therapeutics (CTMX) PT Set at $40.00 by Cantor Fitzgerald

CytomX Therapeutics (NASDAQ:CTMX) has been given a $40.00 price objective by stock analysts at Cantor Fitzgerald in a report issued on Wednesday. The firm presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 69.92% from the company’s current price.

Several other research analysts have also issued reports on the stock. Zacks Investment Research lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 5th. BidaskClub lowered shares of CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, March 30th. ValuEngine upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Bank of America raised their price target on shares of CytomX Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. Finally, Jefferies Group raised their price target on shares of CytomX Therapeutics to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $38.43.

CytomX Therapeutics stock opened at $23.54 on Wednesday. CytomX Therapeutics has a 52-week low of $23.48 and a 52-week high of $24.17. The company has a market cap of $905.37 million, a price-to-earnings ratio of -20.29 and a beta of 0.95.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Wednesday, March 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.45. CytomX Therapeutics had a negative net margin of 67.88% and a negative return on equity of 92.68%. The firm had revenue of $27.07 million during the quarter, compared to analyst estimates of $10.70 million. sell-side analysts forecast that CytomX Therapeutics will post -1.47 earnings per share for the current year.

In other news, Director Frederick W. Gluck sold 3,819 shares of CytomX Therapeutics stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $30.00, for a total value of $114,570.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Debanjan Ray sold 33,000 shares of CytomX Therapeutics stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $29.99, for a total transaction of $989,670.00. The disclosure for this sale can be found here. Insiders sold a total of 123,578 shares of company stock valued at $3,633,036 in the last quarter. 8.50% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. AMP Capital Investors Ltd increased its stake in shares of CytomX Therapeutics by 64.7% in the 4th quarter. AMP Capital Investors Ltd now owns 66,621 shares of the biotechnology company’s stock valued at $1,406,000 after acquiring an additional 26,183 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of CytomX Therapeutics by 32.9% in the 4th quarter. Renaissance Technologies LLC now owns 715,100 shares of the biotechnology company’s stock valued at $15,096,000 after acquiring an additional 177,200 shares in the last quarter. Redmile Group LLC increased its stake in shares of CytomX Therapeutics by 9.5% in the 4th quarter. Redmile Group LLC now owns 418,680 shares of the biotechnology company’s stock valued at $8,838,000 after acquiring an additional 36,409 shares in the last quarter. Two Sigma Investments LP increased its stake in shares of CytomX Therapeutics by 12.0% in the 4th quarter. Two Sigma Investments LP now owns 153,340 shares of the biotechnology company’s stock valued at $3,237,000 after acquiring an additional 16,479 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in shares of CytomX Therapeutics by 47.3% in the 3rd quarter. Wells Fargo & Company MN now owns 60,739 shares of the biotechnology company’s stock valued at $1,104,000 after acquiring an additional 19,506 shares in the last quarter. Institutional investors own 68.83% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit